Evidence map›Paper›PMID 30153832›Full record

ArticleCardiovascular diabetology2018

Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter?

Alexander Tenenbaum, Enrique Z Fisman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Omega-3 for the prevention of cardiovascular diseases: meta-analysis and trial-sequential analysis.European journal of hospital pharmacy : science and practice · 2022
    Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Recent advances in nanocarriers for nutrient delivery.Drug delivery and translational research · 2022
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alexander TenenbaumSackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.
Enrique Z FismanSackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel. zfisman@post.tau.ac.il.ORCID 0000-0001-7055-4488

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a vast disagreement in relation to the possible beneficial effects of omega-3 polyunsaturated fatty acids (omega-3 PUFA) supplementation in patients with diabetes and cardiovascular disease. The conflicting results between the various original studies and meta-analyses could be partially explained as a result of variable supplementation dosage and duration, either of which may modify the effects of omega-3 PUFA on cardio-metabolic biomarkers. Meta-analyses are limited usually by the inability to draw inferences regarding dosage, duration and the interaction of dosage and duration of omega-3 PUFA intake. Even so, almost all endpoints in the so-called "negative" meta-analyses leaned toward a trend for benefit with a near 10% reduction in cardiovascular outcomes and a borderline statistical significance. Many trials included in these meta-analyses tested an insufficient daily dose of omega-3 PUFA of less than 1000 mg. Probably, the consistent cardiovascular effects of omega-3 PUFA supplements could be expected only with daily doses above 2000 mg.

Indexed as

Dietary SupplementsCardiovascular DiseasesDiabetes MellitusDose-Response Relationship, DrugEvidence-Based MedicineFatty Acids, Omega-3HumansProtective FactorsRisk FactorsTime FactorsTreatment OutcomeFatty Acids, Omega-3AtherogenesisCardiovascular risk reductionCoronary artery diseaseDyslipidemiaHypertriglyceridemiaOmega 3 supplementsPolyunsaturated fatty acidsType 2 diabetes mellitus

Identifiers

PMID30153832
PMCPMC6112138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.